Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in giant cell arteritis
MOH_2019-06-12_006007Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in giant cell arteritis (GCA) (4 arms), sponsored by Sanofi. Started Jan 2019; status: completed.
02
Drugs
sarilumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on MOH_2019-06-12_006007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-12_006007.